New cancer drug enters human testing for Tough-to-Treat cancers

NCT ID NCT06858813

Recruiting now Disease control Sponsor: AbbVie Source: ClinicalTrials.gov ↗

Summary

This is the first study in people testing an experimental drug called ABBV-324 for advanced liver cancer or a type of lung cancer. The main goals are to find a safe dose, see how the body processes the drug, and check if it helps shrink tumors. The study will enroll about 232 adults whose cancer has progressed after standard treatments.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

City of Hope - Orange County Lennar Foundation Cancer Center /ID# 276120
RECRUITING

Irvine, California, 92618, United States
City of Hope National Medical Center /ID# 270526
RECRUITING

Duarte, California, 91010, United States
Fdi Clinical Research /ID# 272960
COMPLETED

San Juan, 00927, Puerto Rico
Hadassah Medical Center-Hebrew University /ID# 271235
RECRUITING

Jerusalem, 91120, Israel
Hospital Universitario Fundacion Jimenez Diaz /ID# 272718
RECRUITING

Madrid, 28040, Spain
Hospital Universitario HM Sanchinarro /ID# 272719
RECRUITING

Madrid, 28050, Spain
Kansai Medical University Hospital /ID# 272884
RECRUITING

Hirakata-shi, Osaka, 573-1191, Japan
Memorial Sloan Kettering Cancer Center /ID# 271228
RECRUITING

New York, New York, 10021-3459, United States
Nanfang Hospital - Southern Medical University /ID# 276916
RECRUITING

Guangzhou, Guangdong, 510000, China
National Cancer Center Hospital /ID# 270583
RECRUITING

Chuo-Ku, Tokyo, 104-0045, Japan
National Cancer Center Hospital East /ID# 270585
RECRUITING

Kashiwa-shi, Chiba, 277-8577, Japan
National Taiwan University Hospital /ID# 270593
RECRUITING

Taipei, 100, Taiwan
Rabin Medical Center. /ID# 271236
RECRUITING

Petah Tikva, 4941492, Israel
Rambam Health Care Campus /ID# 270604
RECRUITING

Haifa, 3109601, Israel
SCRI Oncology Partners /ID# 272750
RECRUITING

Nashville, Tennessee, 37203, United States
Thomas Jefferson University Sidney Kimmel Cancer Center /ID# 276269
RECRUITING

Philadelphia, Pennsylvania, 19107, United States
UC Irvine Medical Center /ID# 270507
RECRUITING

Orange, California, 92868-3201, United States
UCLA - Santa Monica /ID# 275995
RECRUITING

Santa Monica, California, 90404, United States
USC Norris Comprehensive Cancer Center /ID# 271573
RECRUITING

Los Angeles, California, 90033, United States
University of Chicago Medical Center /ID# 270517
RECRUITING

Chicago, Illinois, 60637, United States
Washington University /ID# 275757
RECRUITING

St Louis, Missouri, 63110, United States
Zhongshan Hospital Fudan University /ID# 276917
RECRUITING

Shanghai, Shanghai Municipality, 200032, China

Conditions

Explore the condition pages connected to this study.

HEPATOCELLULAR CANCER SQUAMOUS-CELL NON-SMALL CELL LUNG CANCER